Discussion
A pilot clinical trial in the U.S. is enrolling people with relapsing-remitting multiple sclerosis (RRMS) to test Setpoint Medical’s implantable nerve stimulation device, which is designed to reduce inflammation and promote myelin repair. The trial (NCT06796504) is enrolling up to 60 people, ages 22-50, and will evaluate…